• •Researchers developed a modified CRISPR enzyme that targets and disintegrates cancer cell DNA upon activation.
• •The experimental therapy specifically triggers apoptosis in malignant cells while leaving healthy tissue intact in early trials.
• •Long-term efficacy and potential off-target effects in complex human biological systems remain unverified at this stage.

Scientists have engineered a CRISPR-based enzyme capable of inducing cell death by systematically shredding the DNA of cancer cells. While traditional CRISPR applications focus on gene editing to repair mutations, this method repurposes the technology as a targeted destructive mechanism. Unlike standard chemotherapy, which often damages healthy cells, this approach seeks high specificity; however, the mechanism's stability over extended treatment cycles remains unproven. Whether this technique can be scaled for clinical use depends on overcoming the significant delivery challenges inherent in systemic enzyme therapy.